1h Free Analyst Time
SummarySpeak directly to the analyst to clarify any post sales queries you may have.
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Anaplastic Astrocytoma - Pipeline Review, H2 2020, provides an overview of the Anaplastic Astrocytoma (Oncology) pipeline landscape.
Anaplastic astrocytoma is a grade III tumor. It accounts for two percent of all brain tumors. It is a type of glioma that develops from star-shaped glial cells (astrocytes), which support nerve cells. Anaplastic astrocytoma grows faster and more aggressively than grade II astrocytomas. The tumor cells are not uniform in appearance and invade neighboring tissue. Symptoms include headache, weakness, clumsiness, difficulty walking and seizures. Anaplastic astrocytoma is common among men and women in their thirties to fifties and is more common in men than women. Treatment of anaplastic astrocytoma depends on the location of the tumor and how far it has progressed and usually involves surgery and radiation therapy, with chemotherapy during or following radiation.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Anaplastic Astrocytoma - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Anaplastic Astrocytoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Anaplastic Astrocytoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Anaplastic Astrocytoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and IND/CTA Filed stages are 2, 11, 17 and 1 respectively. Similarly, the Universities portfolio in Phase II and Phase I stages comprises 2 and 3 molecules, respectively.
Anaplastic Astrocytoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Anaplastic Astrocytoma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Anaplastic Astrocytoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Anaplastic Astrocytoma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Anaplastic Astrocytoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Anaplastic Astrocytoma (Oncology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Anaplastic Astrocytoma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Anaplastic Astrocytoma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
IntroductionAnaplastic Astrocytoma - Overview
Anaplastic Astrocytoma - Therapeutics Development
Anaplastic Astrocytoma - Therapeutics Assessment
Anaplastic Astrocytoma - Companies Involved in Therapeutics Development
Anaplastic Astrocytoma - Drug Profiles
Anaplastic Astrocytoma - Dormant Projects
Anaplastic Astrocytoma - Discontinued Products
Anaplastic Astrocytoma - Product Development Milestones
Appendix
List of Tables
- Number of Products under Development for Anaplastic Astrocytoma, H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products under Development by Universities/Institutes, H2 2020
- Products under Development by Companies, H2 2020
- Products under Development by Universities/Institutes, H2 2020
- Number of Products by Stage and Target, H2 2020
- Number of Products by Stage and Mechanism of Action, H2 2020
- Number of Products by Stage and Route of Administration, H2 2020
- Number of Products by Stage and Molecule Type, H2 2020
- Anaplastic Astrocytoma - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H2 2020
- Anaplastic Astrocytoma - Pipeline by AbbVie Inc, H2 2020
- Anaplastic Astrocytoma - Pipeline by Adastra Pharmaceuticals Inc, H2 2020
- Anaplastic Astrocytoma - Pipeline by Aettis Inc, H2 2020
- Anaplastic Astrocytoma - Pipeline by AngioChem Inc, H2 2020
- Anaplastic Astrocytoma - Pipeline by Apexigen Inc, H2 2020
- Anaplastic Astrocytoma - Pipeline by Astellas Pharma Inc, H2 2020
- Anaplastic Astrocytoma - Pipeline by Bayer AG, H2 2020
- Anaplastic Astrocytoma - Pipeline by Berg LLC, H2 2020
- Anaplastic Astrocytoma - Pipeline by Boehringer Ingelheim International GmbH, H2 2020
- Anaplastic Astrocytoma - Pipeline by Bristol-Myers Squibb Co, H2 2020
- Anaplastic Astrocytoma - Pipeline by Calithera Biosciences Inc, H2 2020
- Anaplastic Astrocytoma - Pipeline by Candel Therapeutics, H2 2020
- Anaplastic Astrocytoma - Pipeline by CDG Therapeutics Inc, H2 2020
- Anaplastic Astrocytoma - Pipeline by Deciphera Pharmaceuticals Inc, H2 2020
- Anaplastic Astrocytoma - Pipeline by Everfront Biotech Inc, H2 2020
- Anaplastic Astrocytoma - Pipeline by Geneos Therapeutics Inc, H2 2020
- Anaplastic Astrocytoma - Pipeline by Ipsen SA, H2 2020
- Anaplastic Astrocytoma - Pipeline by Kazia Therapeutics Ltd, H2 2020
- Anaplastic Astrocytoma - Pipeline by Mustang Bio Inc, H2 2020
- Anaplastic Astrocytoma - Pipeline by Nascent Biotech Inc, H2 2020
- Anaplastic Astrocytoma - Pipeline by Novartis AG, H2 2020
- Anaplastic Astrocytoma - Pipeline by Oncoceutics Inc, H2 2020
- Anaplastic Astrocytoma - Pipeline by Orbus Therapeutics Inc, H2 2020
- Anaplastic Astrocytoma - Pipeline by Pfizer Inc, H2 2020
- Anaplastic Astrocytoma - Pipeline by PTC Therapeutics Inc, H2 2020
- Anaplastic Astrocytoma - Pipeline by Taiho Oncology Inc, H2 2020
- Anaplastic Astrocytoma - Pipeline by TheraBiologics Inc, H2 2020
- Anaplastic Astrocytoma - Pipeline by Wayshine Biopharma Inc, H2 2020
- Anaplastic Astrocytoma - Dormant Projects, H2 2020
- Anaplastic Astrocytoma - Dormant Projects, H2 2020 (Contd..1), H2 2020
- Anaplastic Astrocytoma - Discontinued Products, H2 2020
List of Figures
- Number of Products under Development for Anaplastic Astrocytoma, H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products under Development by Universities/Institutes, H2 2020
- Number of Products by Top 10 Targets, H2 2020
- Number of Products by Stage and Top 10 Targets, H2 2020
- Number of Products by Top 10 Mechanism of Actions, H2 2020
- Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
- Number of Products by Top 10 Routes of Administration, H2 2020
- Number of Products by Stage and Top 10 Routes of Administration, H2 2020
- Number of Products by Top 10 Molecule Types, H2 2020
- Number of Products by Stage and Top 10 Molecule Types, H2 2020
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- A. Menarini Industrie Farmaceutiche Riunite Srl
- AbbVie Inc
- Adastra Pharmaceuticals Inc
- Aettis Inc
- AngioChem Inc
- Apexigen Inc
- Astellas Pharma Inc
- Bayer AG
- Berg LLC
- Boehringer Ingelheim International GmbH
- Bristol-Myers Squibb Co
- Calithera Biosciences Inc
- Candel Therapeutics
- CDG Therapeutics Inc
- Deciphera Pharmaceuticals Inc
- Everfront Biotech Inc
- Geneos Therapeutics Inc
- Ipsen SA
- Kazia Therapeutics Ltd
- Mustang Bio Inc
- Nascent Biotech Inc
- Novartis AG
- Oncoceutics Inc
- Orbus Therapeutics Inc
- Pfizer Inc
- PTC Therapeutics Inc
- Taiho Oncology Inc
- TheraBiologics Inc
- Wayshine Biopharma Inc
